Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis Pharmaceuticals has launched once-daily Arcapta Neohaler (indacaterol inhalation powder) 75mcg in the US.
Subscribe to our email newsletter
The once-daily, long-acting beta2-agonist (LABA) approved in the US is an inhaled, steroid-free chronic obstructive pulmonary disease (COPD) treatment.
The product is indicated for the long-term maintenance bronchodilator treatment of airflow obstruction in adult patients with COPD, including chronic bronchitis and/or emphysema.
Novartis Pharmaceuticals president Andre Wyss said Arcapta Neohaler represents an important new treatment option for the 14 million Americans living with COPD.
"The launch of Arcapta Neohaler is a significant milestone as we continue to establish a strong respiratory presence in the US market," Wyss added.